Charles Schwab Investment Management Inc. Invests $2.73 Million in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Charles Schwab Investment Management Inc. bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the fourth quarter, Holdings Channel reports. The firm bought 156,784 shares of the company’s stock, valued at approximately $2,731,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth about $31,000. SG Americas Securities LLC purchased a new position in Bicara Therapeutics in the 4th quarter worth approximately $147,000. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $229,000. Barclays PLC acquired a new stake in Bicara Therapeutics in the third quarter valued at approximately $255,000. Finally, Jane Street Group LLC purchased a new stake in shares of Bicara Therapeutics during the third quarter valued at approximately $309,000.

Bicara Therapeutics Stock Up 2.3 %

BCAX opened at $13.40 on Friday. The business has a 50-day moving average of $13.01. Bicara Therapeutics Inc. has a 1-year low of $11.10 and a 1-year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, April 1st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BCAX shares. Cantor Fitzgerald restated an “overweight” rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. HC Wainwright raised their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.